Shinji Saiki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7052814/publications.pdf

Version: 2024-02-01

37	5,450	21	36
papers	citations	h-index	g-index
37	37 docs citations	37	10349
all docs		times ranked	citing authors

#	Article	IF	CITATIONS
1	PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. Journal of Cell Biology, 2010, 189, 211-221.	5.2	1,600
2	Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nature Chemical Biology, 2008, 4, 295-305.	8.0	739
3	Lysosomal positioning coordinates cellular nutrient responses. Nature Cell Biology, 2011, 13, 453-460.	10.3	726
4	Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy, 2011, 7, 176-187.	9.1	385
5	Huntington's disease: from pathology and genetics to potential therapies. Biochemical Journal, 2008, 412, 191-209.	3.7	373
6	A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Human Molecular Genetics, 2008, 17, 170-178.	2.9	312
7	Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 295-301.	1.9	214
8	PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Letters, 2010, 584, 1073-1079.	2.8	205
9	Symbiotic polyamine metabolism regulates epithelial proliferation and macrophage differentiation in the colon. Nature Communications, 2021, 12, 2105.	12.8	105
10	Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease. Scientific Reports, 2017, 7, 7328.	3.3	95
11	A metabolic profile of polyamines in parkinson disease: A promising biomarker. Annals of Neurology, 2019, 86, 251-263.	5.3	74
12	Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology, 2018, 90, e404-e411.	1.1	70
13	Molecular pathogenesis of Parkinson's disease: update. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 430-436.	1.9	69
14	Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation. Journal of Neuroscience, 2020, 40, 8618-8628.	3.6	57
15	Connectome analysis with diffusion MRI in idiopathic Parkinson's disease: Evaluation using multi-shell, multi-tissue, constrained spherical deconvolution. NeuroImage: Clinical, 2018, 17, 518-529.	2.7	51
16	Metabolomicsâ€based identification of metabolic alterations in PARK2. Annals of Clinical and Translational Neurology, 2019, 6, 525-536.	3.7	44
17	Regulation by mitophagy. International Journal of Biochemistry and Cell Biology, 2014, 53, 147-150.	2.8	40
18	Extensive hemispheric lesions with radiological evidence of blood–brain barrier integrity in a patient with neuromyelitis optica. Journal of the Neurological Sciences, 2009, 284, 217-219.	0.6	39

#	Article	IF	CITATIONS
19	Neuroprotective effects of memantine via enhancement of autophagy. Biochemical and Biophysical Research Communications, 2019, 518, 161-170.	2.1	36
20	Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neuroscience Letters, 2010, 481, 88-91.	2.1	27
21	Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease. Annals of Clinical and Translational Neurology, 2020, 7, 307-317.	3.7	22
22	A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers. Autophagy, 2021, 17, 1856-1872.	9.1	20
23	Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson's disease: a pilot study. Neurological Sciences, 2021, 42, 4767-4770.	1.9	19
24	p150glued deficiency impairs effective fusion between autophagosomes and lysosomes due to their redistribution to the cell periphery. Neuroscience Letters, 2019, 690, 181-187.	2.1	15
25	p150glued-Associated Disorders Are Caused by Activation of Intrinsic Apoptotic Pathway. PLoS ONE, 2014, 9, e94645.	2.5	14
26	Ethambutol neutralizes lysosomes and causes lysosomal zinc accumulation. Biochemical and Biophysical Research Communications, 2016, 471, 109-116.	2.1	14
27	Non-invasive diagnostic tool for Parkinson's disease by sebum RNA profile with machine learning. Scientific Reports, 2021, 11, 18550.	3.3	14
28	Metabolomic analysis revealed mitochondrial dysfunction and aberrant choline metabolism in MPP+-exposed SH-SY5Y cells. Biochemical and Biophysical Research Communications, 2019, 519, 540-546.	2.1	13
29	Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up. Parkinsonism and Related Disorders, 2021, 84, 139-143.	2.2	12
30	Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review. Movement Disorders, 2021, 36, 1759-1771.	3.9	10
31	Immunocytochemical Monitoring of PINK1/Parkin-Mediated Mitophagy in Cultured Cells. Methods in Molecular Biology, 2017, 1759, 19-27.	0.9	9
32	Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy. PLoS ONE, 2019, 14, e0223113.	2.5	9
33	Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Movement Disorders, 2020, 35, 1438-1447.	3.9	8
34	Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells, 2019, 8, 14.	4.1	5
35	Plasma taurine is an axonal excitability-translatable biomarker for amyotrophic lateral sclerosis. Scientific Reports, 2022, 12, .	3.3	3
36	Metabolomic analysis data of MPP+-exposed SH-SY5Y cells using CE-TOFMS. Data in Brief, 2021, 34, 106707.	1.0	1

#	Article	lF	CITATIONS
37	Diffusion MRI Captures White Matter Microstructure Alterations in PRKN Disease. Journal of Parkinson's Disease, 2021, 11, 1221-1235.	2.8	1